Levi M. T. Winkelman

Levi M. T. Winkelman

Auto-generated profile, based on publicly available information

Levi M. T. Winkelman

Leiden University, Leiden Academic Centre for Drug Research, Division of Cell Systems & Drug Safety

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2025 in Environmental and Molecular Mutagenesis
Verified
Journal Article
Closed access
EDE. Demuynck
E. Demuynck
TVT. Vanhaecke
T. Vanhaecke
ATA. Thienpont
A. Thienpont
DCDavie Cappoen
Davie Cappoen
FGF. Van Goethem
F. Van Goethem
BMBirgit Mertens
Birgit Mertens

13 November 2025 in Communications Biology
Verified
Journal Article
Open access
PDF file
ADAnneloes van der Plas - van Duijn
Anneloes van der Plas - van Duijn
LWLevi M. T. Winkelman
Levi M. T. Winkelman
CLClaire Lensen
Claire Lensen
MDMaaike van Duivendijk
Maaike van Duivendijk
IDIan Derksen
Ian Derksen
FSFerenc A Scheeren
Ferenc A Scheeren
Monoclonal antibodies are important modalities in the treatment of cancer. Post-translational modifications of proteins, such as glycosylation, can affect the binding affinity of therapeutic antibodies. Whether other PTMs modulate therapeutic antibody binding to different surface proteins is currently underexplored. Pyroglutamation is the post-translational cyclization of an N-terminal glutamine or glutamic acid residue into a pyroglutamate by glutaminyl cyclase. In this study, we investigated the impact of pyroglutamation on the binding affinity of three therapeutic antibodies targeting CD47 and TRP1. Here, we show that pyroglutamation on CD47 and TRP1 modulates the binding of anti(α)-CD47 magrolimab and αTRP1 TA99 and flanvotumab. Furthermore, the N-terminal glutamine on CD47 is crucial for effective antibody recognition, while pyroglutamation of TRP1 is involved in trafficking to the cell surface. These findings highlight that the pyroglutamation by glutaminyl cyclase can modulate the binding affinity of antibodies with therapeutic potential.

13 November 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
LWLevi M.T. Winkelman
Levi M.T. Winkelman
EDEmmanuel Demuynck
Emmanuel Demuynck
SBSteven M. Bryce
Steven M. Bryce
MSMaciej Stepnik
Maciej Stepnik
ATAnouck I. Thienpont
Anouck I. Thienpont
JBJoost Beltman
Joost Beltman
Quantitative Adverse Outcome Pathways (qAOPs) help translate mechanistic knowledge into quantitative toxicity predictions; however, their development is constrained by the limited availability and heterogeneity of quantitative data. Here, we investigated the feasibility of developing a qAOP for genotoxicity by modeling quantitative relationships linking DNA alkylation to increased mutations and structural chromosome aberrations through intermediate biological key events (KEs). We compiled and harmonized published concentration-response data from human lymphoblastoid TK6 cells exposed to ethyl methanesulfonate, methyl methanesulfonate, or N-ethyl-N-nitrosourea, covering eight genotoxicity assays representing five KEs with well-established dependencies. We evaluated sources of variability, compared points of departure (PoDs), and quantified relationships between successive events using response-response modeling. Substantial between-study variability could to a limited extent be explained through differences in experimental design while batch effects for individual studies and researchers were substantial. PoD estimates that were calculated from combined results of independent studies with similar experimental design, were often uncertain due to insufficient concentration-response characterization or conflicting results between studies. Nevertheless, response-response modeling suggested a threshold effect for certain key-event relationships (KERs). Specifically, DNA adducts seemed to be triggered at lower concentrations of alkylating agents compared to the subsequent KEs of DNA strand breaks and chromosome aberrations. Furthermore, these fitted response-response models can be used for prediction of downstream KEs from earlier ones. The general approach we developed for BMC analysis followed by response-response modeling is applicable to other AOPs as well. These findings highlight both the feasibility and limitations of using existing data for qAOP development.